Table 1

Baseline demographic and clinical characteristics of the cohort and stratified by use of androgen deprivation therapy (ADT)

Entire cohortADT use during follow-up*
CharacteristicN, %Any ADT, %No ADT, %
Total20 31010 250 (50.5)10 060 (49.5)
Age, years (mean, SD)71.2 (9.1)72.8 (8.2)68.6 (9.1)
Body mass index, n (%)
 <25 kg/m26386 (31.4)3257 (31.8)3129 (31.1)
 25–30 kg/m29069 (44.7)4397 (42.9)4672 (46.4)
 ≥30.03785 (18.6)2001 (19.5)1784 (17.7)
 Unknown1070 (5.3)595 (5.8)475 (4.7)
Smoking status, n (%)
 Current2249 (11.1)1215 (11.9)1034 (10.3)
 Past7880 (38.8)4147 (40.6)3733 (37.1)
 Never9639 (47.5)4596 (44.8)5043 (50.1)
 Unknown542 (2.7)292 (2.9)250 (2.5)
Alcohol-related disorders, n (%)1899 (9.4)937 (9.1)962 (9.6)
Prostate-specific antigen, n (%)
 <4 ng/mL1192 (5.9)250 (2.4)942 (9.4)
 4–10 ng/mL6459 (31.8)1814 (17.7)4645 (46.2)
 ≥10 ng/mL9704 (47.8)6673 (65.1)3031 (30.1)
 Unknown2955 (14.6)1513 (14.8)1442 (14.3)
High-risk season, n (%)10 203 (50.2)5079 (49.6)5124 (50.9)
Previous cancer, n (%)2348 (11.6)1223 (11.9)1125 (11.2)
COPD, n (%)2617 (12.9)1447 (14.1)1170 (11.6)
Asthma, n (%)2366 (11.7)1160 (11.3)1206 (12.0)
Bronchitis, n (%)1540 (7.6)854 (8.3)686 (6.8)
Bronchiectasis, n (%)41 (0.2)18 (0.2)23 (0.2)
Immunosuppressive agents, n (%)167 (0.8)81 (0.8)86 (0.9)
Inhaled bronchodilators, n (%)2519 (12.4)1341 (13.1)1178 (11.7)
Inhaled corticosteroids, n (%)2003 (9.9)1067 (10.4)936 (9.3)
Oral corticosteroids, n (%)1182 (5.8)625 (6.1)557 (5.5)
Non-topical antibiotics, n (%)8719 (42.9)4479 (43.7)4240 (42.2)
Influenza vaccines, n (%)10 444 (51.4)6040 (58.9)4404 (43.8)
Pneumococcal vaccines, n (%)1258 (6.2)691 (6.7)567 (5.6)
  • *ADT use in the first six months during follow-up.